New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 21, 2012
16:39 EDTZLC, VVUS, STJ, SQNM, CRM, TLYS, AETOn The Fly: Closing Wrap
Stocks on Wall Street were higher on the day, the last full trading session of the week ahead of Thursday's holiday and Friday's half day. Jobless data that was in-line with expectations did little to move the markets before the open, but the markets slowly moved higher through the session, although volume remained light. Just after midday, news crossed that a cease fire between Israel and Hamas had been reached, tempering fears that the conflict could escalate to involve other players in the region and have broader economic impacts... ECONOMIC EVENTS: In the U.S., initial jobless claims fell to 410,000, which was in-line with forecasts. Markit's "flash" November flash PMI rose to 52.4 from 51.0 in October. The final November reading of the University of Michigan Sentiment index slipped to 82.7 from its 84.9 preliminary reading. The leading indicators edged up 0.2% in October to 96.0 from 95.8 in September. In Europe, the region's finance ministers and the IMF were unable to reach a bailout agreement for Greece and will meet again on Monday with an eye on resolving the remaining disagreements. In Asia, Japanese exports fell 6.5% in October, lower than expectations for a 4.9% decline... COMPANY NEWS: Salesforce.com's (CRM) Q3 results beat on the top and bottom lines and RW Baird and Wells Fargo reiterated their Outperform ratings on the stock following the report, and shares of Salesforce.com traded higher on the session, settling up $12.88, or 8.83%, to $158.78... MAJOR MOVERS: Among notable gainers were shares of VIVUS (VVUS), up $1.38, or 13.33%, to $11.73 after Aetna (AET) posted a policy revision that expands coverage of the company's weight-loss drug Qsymia. Also higher were shares of Sequenom (SQNM), up 56c, or 15.18%, to $4.25 after a committee of the American College of Obstetricians and Gynecologists recommended that cell-free fetal DNA testing be offered to certain at-risk patients. Among the noteworthy were shares of Zale (ZLC), down over $2.23, or 29.97%, to $5.21, and Tilly's (TLYS), down $2.69, or 17.18%, to $12.97 after reporting earnings. Also lower were shares of St. Jude Medical (STJ), which fell $4.34, or 12.15%,to $31.37 after an FDA inspection report cited serious flaws in its oversight of design changes in its Durata line of defibrillator leads... INDICES The Dow was up 48.38, or 0.38%, to 12,836.89; the S&P 500 was up 3.22, or 0.23%, to 1,391.03;the Nasdaq was up 9.87, or 0.34%, to 2,926.55.
News For CRM;VVUS;AET;SQNM;ZLC;TLYS;STJ From The Last 14 Days
Check below for free stories on CRM;VVUS;AET;SQNM;ZLC;TLYS;STJ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 22, 2014
08:54 EDTCRMSaaS fundamentals remain strong, buy pullback, says Morgan Stanley
Morgan Stanley said SaaS fundamentals remain strong and corporate spending and secular drivers remain strong. The analyst would use the pullback to buy favorite names that include ServiceNow (NOW), Salesforce.com (CRM), Veeva (VEEV) and Workday (WDAY).
05:47 EDTCRMStocks with implied volatility movement; JCP CRM
Subscribe for More Information
April 17, 2014
12:53 EDTAETOn The Fly: Midday Wrap
Subscribe for More Information
10:51 EDTAETHealth insurers slide after UnitedHealth results, cautious comments
Shares of a number of health insurers are falling after the largest company in the sector, UnitedHealth (UNH), reported slightly higher than expected first quarter profit but lower than expected revenue. WHAT'S NEW: UnitedHealth's first quarter earnings per share came in at $1.10, versus the consensus outlook of $1.09. The insurer reported revenue of $31.71B, compared with the consensus outlook of $31.99B. Taxes levied by the Affordable Care Act and weak funding of Medicare Advantage by the government weighed on UnitedHealth's earnings, the company stated. Also pushing down the company's earnings was "a very expensive," new Hepatitis C therapy, UnitedHealth stated on its earnings conference call. Hepatitis C treatments cost UnitedHealth hundreds of millions of dollars in the first quarter, the company stated, though it also noted that demand for the treatments should drop going forward as initial pent-up demand for them starts to decline. The company indicated that it was looking to be reimbursed by states for the money it is spending on hepatitis vaccines for Medicaid patients. Meanwhile, UnitedHealth reiterated its fiscal 2014 EPS guidance of $5.40-$5.60 and its fiscal 2014 revenue guidance of $128B-$129B. PRICE ACTION: In mid-morning trading, UnitedHealth sank 3.7% to $75.31. Other health insurers also declined, with WellPoint (WLP) dropping 4% to $91.89, Aetna (AET) falling 3.3% to $67.54, Humana (HUM) declining 2.25% to $106.35, and Health Net (HNT) sliding 1% to $31.74.
08:00 EDTSTJSt. Jude Medical price target lowered to $47 from $51 at Canaccord
Subscribe for More Information
April 16, 2014
15:39 EDTSTJBoston Scientific CRT-D approval neutral for St. Jude, says Wells Fargo
Subscribe for More Information
10:08 EDTAETUnitedHealth retreats after Citi cuts rating on shares
Subscribe for More Information
10:00 EDTSTJSt. Jude Medical falls 4.3%
Subscribe for More Information
08:33 EDTSTJSt. Jude Medical sees total Q2 CRM sales $705M-$735M
Subscribe for More Information
07:34 EDTSTJSt. Jude Medical sees FY14 consolidated adjusted EPS $3.95-$4.00
Subscribe for More Information
07:33 EDTSTJSt. Jude Medical sees Q2 consolidated adjusted EPS 99c-$1.01, consensus $1.00
Sees Q2 revenue $1.38B-$1.46B, consensus $1.44B.
07:31 EDTSTJSt. Jude Medical reports Q1 adjusted EPS 96c, consensus 95c
Subscribe for More Information
April 15, 2014
15:19 EDTSTJNotable companies reporting before tomorrow's open
Subscribe for More Information
09:23 EDTSTJBarclays medical supplies/devices analysts hold analyst/industry conference call
Subscribe for More Information
06:32 EDTAETPatients paying much more for specialty drugs, NY Times says
The amount that patients with certain diseases must pay for specialty drugs has increased significantly, a research firm reported, according to The New York Times. Meanwhile, consumers' use of health care increased in 2013 for the firm time in three years, the newspaper quoted the firm, the IMS Institute for Healthcare Informatics, as saying. Publicly traded drug makers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded health insurers include AMERIGROUP (AGP), Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Healthspring (HS), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH), WellCare (WCG) and WellPoint (WLP).Reference Link
April 11, 2014
13:36 EDTTLYSGap falls after experiencing sharp decline in March SSS
Subscribe for More Information
10:05 EDTAETAetna, Tenet form accountable care collaboration in San Antonio
Aetna (AET), Tenetís (THC) Baptist Health System and HealthTexas Medical Group announced an accountable care collaboration and the introduction of the Aetna Whole Health product in the San Antonio area. The health plans, designed for fully insured customers with employees who live or work in Bexar, Guadalupe, Comal and Kendall counties, will be available on July 1.
08:49 EDTCRMBoston Properties signs 714,000 square foot lease with Salesforce.com
Subscribe for More Information
07:06 EDTVVUSVIVUS announces avanafil clinical data presentation
Subscribe for More Information
April 10, 2014
09:01 EDTCRMSalesforce.com should be bought ahead of results, says Pacific Crest
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use